NCT02947087View on ClinicalTrials.gov

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

November 13, 2021

Study Completion Date

November 13, 2022

Conditions
Chronic Pancreatitis
Interventions
DRUG

Prolastin-C

Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation

DRUG

Placebo

Patients will receive saline on day 0, 7, 14, and 21 days of transplantation

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Medical University of South Carolina

OTHER

NCT02947087 - Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis | Biotech Hunter | Biotech Hunter